Is the business good?
How good a business is NKTR?
Nektar Therapeutics keeps −242% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−242%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +76%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 220%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −278% |
| FY2021 | −438% |
| FY2022 | −409% |
| FY2023 | −293% |
| FY2024 | −107% |
| FY2025 | −254% |
Details›
- Operating margin12 months to Q1 2026
- −242%
- Net margin12 months to Q1 2026
- −284%
- Free cash flow margin
- −367%
- R&D as % of revenue
- 220%
- Revenue, trailing twelve months
- $56M
- Free cash flow, trailing twelve months
- −$204M
- Net income, trailing twelve months
- −$158M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.